new BindingDB logo
myBDB logout

88 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27692854 100 N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.EBI Boehringer Ingelheim Pharmaceuticals
26631321 37 Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity.EBI Bristol-Myers Squibb Company
25766632 31 Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2).EBI Westf£lische Wilhelms-Universit£t M£nster
25893046 77 Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5.EBI Bristol-Myers Squibb Company
25666912 39 When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonists.EBI Leiden University
25453791 5 Design and synthesis of novel small molecule CCR2 antagonists: evaluation of 4-aminopiperidine derivatives.EBI TBA
24685539 44 The discovery and SAR of cyclopenta[b]furans as inhibitors of CCR2.EBI Janssen Research and Development, LLC
24613378 33 Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists.EBI Bristol-Myers Squibb Company
23916257 54 Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists.EBI Janssen Research and Development, L.L.C.
24900633 11 Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.EBI Amgen Inc.
24900677 8 Targeting CCR2 Receptor To Treat Inflammation Diseases and Disorders.EBI Therachem Research Medilab (India) Pvt. Ltd.
23294701 49 A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.EBI Janssen Pharmaceutical Research& Development, L.L.C.
23182090 92 Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.EBI Janssen Research and Development, LLC
20493592 25 Validated QSAR analysis of some diaryl substituted pyrazoles as CCR2 inhibitors by various linear and nonlinear multivariate chemometrics methods.EBI Tehran University of Medical Sciences
20627722 89 Identification of a sulfonamide series of CCR2 antagonists.EBI GlaxoSmithKline Medicines Research Centre
23079519 86 In vivo activity of an azole series of CCR2 antagonists.EBI GlaxoSmithKline Research and Development
24900425 72 Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 Antagonist as a Development Candidate.EBI TBA
23075267 85 Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.EBI Bristol-Myers Squibb Company
22931505 69 Chemokine receptor antagonists.EBI National Heart and Lung Institute
22939233 23 Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.EBI Bristol-Myers Squibb Company
22608963 109 The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.EBI AstraZeneca
24900280 81 Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.EBI TBA
22475558 82 Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.EBI Bristol-Myers Squibb Company
18487045 35 Substituted dipiperidine alcohols as potent CCR2 antagonists.EBI Johnson& Johnson Pharmaceutical Research and Development
18313297 107 Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series.EBI Deltagen Research Laboratories (Former CombiChem, Inc.
18215519 4 Conformational studies of 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists leading to new spirocyclic antagonists.EBI Merck Research Laboratories
18232650 35 Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.EBI TBA
17046269 86 Design and synthesis of Rho kinase inhibitors (II).EBI Kirin Brewery Co. Ltd
16821774 86 Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.EBI Ono Pharmaceutical Co., Ltd.
16198561 99 Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.EBI Novartis Institutes for BioMedical Research
11931608 17 Inhibition of protein-protein association by small molecules: approaches and progress.EBI Pfizer Global Research and Development
24900329 49 Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.EBI TBA
22225639 29 Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).EBI Bristol-Myers Squibb Company
22061641 49 The discovery of novel cyclohexylamide CCR2 antagonists.EBI Johnson& Johnson Pharmaceutical Research and Development
22047688 51 CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.EBI GlaxoSmithKline
21940167 12 Design and synthesis of a library of chemokine antagonists.EBI Novartis Institutes of Biomedical Research
21917454 159 Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.EBI Johnson& Johnson Pharmaceutical Research and Development
21783361 90 Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.EBI Johnson& Johnson Pharmaceutical Research and Development
21315584 74 Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile.EBI Pfizer Inc.
21341682 37 Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.EBI Telik, Inc.
21316220 34 Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs.EBI Pfizer Inc.
21295478 81 Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.EBI Incyte Corporation
21036044 43 Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.EBI Incyte Corporation
20346664 27 gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.EBI Bristol-Myers Squibb Company
20297846 33 Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI Genzyme Corp.
20223662 174 Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.EBI Yangji Chemicals
19674898 31 Spiropiperidine CCR5 antagonists.EBI Roche Palo Alto LLC
19481449 51 Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.EBI Bristol-Myers Squibb Company
19237282 47 Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.EBI Merck Research Laboratories
19131247 42 Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.EBI Bristol-Myers Squibb Company
19014885 32 Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.EBI Roche Palo Alto LLC
18990568 15 Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.EBI Johnson & Johnson Pharmaceutical Research and Development
18722120 42 Synthesis and evaluation of cis-3,4-disubstituted piperidines as potent CC chemokine receptor 2 (CCR2) antagonists.EBI Bristol-Myers Squibb Company
17715128 6 Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.EBI Université Libre de Bruxelles
18258426 47 QSAR studies on CCR2 antagonists with chiral sensitive hologram descriptors.EBI National Institute of Pharmaceutical Education and Research (NIPER)
18226895 29 Probing the structural and topological requirements for CCR2 antagonism: holographic QSAR for indolopiperidine derivatives.EBI National Institute of Pharmaceutical Education and Research (NIPER)
18164199 34 Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists.EBI Merck Research Laboratories
17929797 34 Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists.EBI Johnson & Johnson Pharmaceutical Research and Development
17869105 42 Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.EBI Johnson & Johnson Pharmaceutical Research and Development
17720492 107 Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2).EBI Bristol-Myers Squibb Company
17587570 34 Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma.EBI Johnson & Johnson Pharmaceutical Research and Development
17482462 60 3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2.EBI Merck Research Laboratories
17461566 11 Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists.EBI Merck Research Laboratories
17092717 59 Alpha-aminothiazole-gamma-aminobutanoic amides as potent, small molecule CCR2 receptor antagonists.EBI Merck Research Laboratories
17088058 40 Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.EBI Merck Research Laboratories
17084087 36 Design and synthesis of rho kinase inhibitors (III).EBI Kirin Brewery Co. Ltd.
16884289 26 Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.EBI Merck Research Laboratories
16870431 54 4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.EBI Merck Research Laboratories
16698264 37 Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.EBI Merck Research Laboratories
16539392 29 Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.EBI Takeda Pharmaceutical Company Limited
15863339 29 Identification of chemokine receptor CCR4 antagonist.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15771462 125 Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.EBI Pharmaceutical Research Institute
15454236 36 Small molecule antagonists of the CCR2b receptor. Part 2: Discovery process and initial structure-activity relationships of diamine derivatives.EBI Deltagen Research Laboratories
15454235 29 Small molecule inhibitors of the CCR2b receptor. Part 1: Discovery and optimization of homopiperazine derivatives.EBI Institute for Bio-medical Research
14698169 53 N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor.EBI AstraZeneca
12954060 4 CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.EBI GlaxoSmithKline
11720852 51 Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11720851 52 Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11514164 36 Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.EBI GlaxoSmithKline Pharmaceuticals
11311066 76 Design, synthesis, and discovery of a novel CCR1 antagonist.EBI Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
11206474 51 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.EBI Merck Research Laboratories
10969972 39 CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.EBI SmithKline Beecham Pharmaceuticals
10821717 29 Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.EBI Takeda Chemical Industries, Ltd.
18588282 63 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.BDB Johnson & Johnson Pharmaceutical